Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance

Phio Pharmaceuticals Corp.

22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.
Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.
PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.
One Merkel cell carcinoma patient had partial response; no disease progression in any patient.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.